Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend? XmAb? Antibody Technology in Investigational Antibodies to Treat COVID-19

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor?s Xtend? Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, t

Click to view original post